Inventor · disambiguated record
Joel Goldstein
Also filed as: GOLDSTEIN JOEL · GOLDSTEIN JOEL D
17 granted patents·16 pending applications·1,294 citations·filing 1987–2024
95Inventor score
Top patents by PatentIndex Score
33 records- 0198US5837243ATherapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1996·Granted Nov 17, 1998·545 cites·18 claims
- 0297US6270765B1Therapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1998·Granted Aug 7, 2001·215 cites·9 claims
- 0394US10633444B2Agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2019·Granted Apr 28, 2020·12 cites·8 claims
- 0493US6410690B1Therapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1995·Granted Jun 25, 2002·91 cites·17 claims
- 0593US6395272B1Therapeutic compounds comprised of anti-Fc receptor antibodiesMEDEREX INC·Filed 1998·Granted May 28, 2002·127 cites·6 claims
- 0693US6365161B1Therapeutic compounds comprised of anti-FC receptor binding agentsMEDAREX INC·Filed 1999·Granted Apr 2, 2002·113 cites·20 claims
- 0792US6682928B2Cells expressing anti-Fc receptor binding componentsMEDAREX INC·Filed 1998·Granted Jan 27, 2004·89 cites·24 claims
- 0890US11332537B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2021·Granted May 17, 2022·1 cites·26 claims
- 0990US10941201B2Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodiesCELLDEX THERAPEUTICS INC·Filed 2020·Granted Mar 9, 2021·2 cites·17 claims
- 1086US2025115663A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1185US2025346671A1Anti-pd-l1 antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1282US10865244B2Nucleic acids encoding agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2017·Granted Dec 15, 2020·1 cites·11 claims
- 1382US4895716AStabilized formulations of gamma interferonsBIOGEN INC·Filed 1987·Granted Jan 23, 1990·30 cites·14 claims
- 1476US2022324990A1Anti-cd27 and anti-pd-l1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1575US2025059291A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1671US11459393B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·0 cites·7 claims
- 1771US2021147538A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1869US5714575ANucleic acids sequence, stress-induced proteins and uses thereofUNIV NEW JERSEY MED·Filed 1994·Granted Feb 3, 1998·29 cites·3 claims
- 1968US5599808AAqueous indolocarbazole solutionsCEPHALON INC·Filed 1995·Granted Feb 4, 1997·32 cites·24 claims
- 2064US12297266B2Agonistic antibodies that bind human CD40 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2017·Granted May 13, 2025·0 cites·19 claims
- 2163US7316812B2Cells expressing anti-Fc receptor binding componentsCELLDEX THERAPEUTICS INC·Filed 2004·Granted Jan 8, 2008·0 cites·25 claims
- 2261US2024409639A1Anti-ilt4 and anti-pd-1 bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2359US2024417459A1Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereofCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2459US2024117057A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2556US2024109961A1Treatment of chronic prurigoCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2651US6333191B1Nucleic acids sequence, stress-induced proteins and uses thereofUNIV NEW JERSEY MED·Filed 1998·Granted Dec 25, 2001·7 cites·11 claims
- 2748US2018044429A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2848US2022177593A1Anti-axl antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2947US2009306348A1Antibody FormulationIMCLONE SYSTEMS INC·Filed 2007·Application pending·0 cites
- 3044US2010158925A1Lyophilized formulations of anti-egfr antibodiesAGARKHED MEERA·Filed 2007·Application pending·0 cites
- 3141US2002164342A1Recombinant cat allergen, Fel dI, expressed in baculovirus for diagnosis and treatment of cat allergyFiled 2002·Application pending·0 cites
- 3237US2006154334A1Method of producing an antibody to epidermal growth factor receptorTARNOWSKI JOSEPH·Filed 2005·Application pending·0 cites
- 3335US2010260766A1Stable antibody formulationsSRIVASTAVA ARVIND·Filed 2008·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Joel Goldstein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →